

> Nausea & vomiting common (NEJM 2016;374:1356; 375:134 & 177)


# CHEMO AND IMMUNORX SIDE EFFECTS

_Nausea & vomiting common_ (_NEJM_ 2016;374:1356; 375:134 & 177)

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Select Adverse Effects from Chemotherapy</b></p></td></tr><tr><td><p><b>Toxicity</b></p></td><td><p><b>Common Agents</b></p></td><td><p><b>Comments</b></p></td></tr><tr><td rowspan="6"><p><b>Cardiotoxicity</b></p><p><span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>6;375;</span><span>1</span><span>457)</span></p></td><td><p><b>Anthracyclines</b></p></td><td><p>Dose-dependent CMP; ✔ EF pre-Rx</p></td></tr><tr><td><p>5-FU</p></td><td><p>Spasm → ischemia; CCB may prevent</p></td></tr><tr><td><p><b>Trastuzumab</b></p></td><td><p>CMP, esp with anthracycline, ✔ EF pre-Rx</p></td></tr><tr><td><p>Tyrosine kinase inhib (TKI)</p></td><td><p>QTc prolongation, CMP, angina</p></td></tr><tr><td><p>Cyclophosphamide</p></td><td><p>Myopericarditis (esp. in BMT)</p></td></tr><tr><td><p>Cisplatin</p></td><td><p>HypoMg → arrhythmia, ischemia</p></td></tr><tr><td rowspan="5"><p><b>Pulmonary</b></p><p><span>(</span><span><i>Sem Oncol</i></span> <span>2006;33:98)</span></p></td><td><p>Busulfan</p></td><td><p>~8% fibrosis or DAH; if severe → steroids</p></td></tr><tr><td><p><b>Bleomycin</b></p></td><td><p>~10% IPF; d/c drug, Rx: steroids</p></td></tr><tr><td><p>TKI (esp. dasatinib)</p></td><td><p>Pleural effusion</p></td></tr><tr><td><p>Cyclophosphamide</p></td><td><p>Pneumonitis, progressive fibrosis; Rx: d/c</p></td></tr><tr><td><p><b>Bevacizumab</b></p></td><td><p>Pulm hemorrhage (esp. NSCLC)</p></td></tr><tr><td rowspan="3"><p><b>Nephrotoxicity/ urologic toxicity</b></p></td><td><p>Platinum Rx (<b>cisplatin</b>)</p></td><td><p>Esp. proximal tubule; pretreat with IV saline</p></td></tr><tr><td><p>Methotrexate</p></td><td><p>Via deposition; Rx: alkalinize urine, IVF</p></td></tr><tr><td><p>Cyclophosphamide</p></td><td><p>Hemorrhagic cystitis; Rx: Mesna</p></td></tr><tr><td rowspan="5"><p><b>Neurotoxicity</b></p><p><span>(</span><span><i>Sem Oncol</i></span> <span>2006;33:324)</span></p></td><td><p>Platinum Rx (<b>cisplatin</b>)</p></td><td><p>“Stocking-glove;” Ppx: vit E <span>(</span><span><i>JCO</i></span> <span>2003;2</span><span>1</span><span>:927)</span></p></td></tr><tr><td><p><b>Cytarabine</b></p></td><td><p>Cerebellar toxicity (irreversible 5–10%)</p></td></tr><tr><td><p>Methotrexate (esp. intrathecal)</p></td><td><p>Late leukoenceph, meningitis; reverse with intrathecal glucarpidase, leucovorin</p></td></tr><tr><td><p>Ifosfamide</p></td><td><p>Enceph; Rx: methylene blue, thiamine</p></td></tr><tr><td><p><b>Taxanes, vincristine</b></p></td><td><p>Sensorimotor long fiber neuropathy</p></td></tr><tr><td rowspan="3"><p><b>Hepatotoxicity</b></p><p><span>(</span><span><i>Sem Oncol</i></span> <span>2006;33:50)</span></p></td><td><p>TKI (eg, imatinib, nilotinib)</p></td><td><p>↑ LFTs, rarely necrosis; Rx: d/c ± steroids</p></td></tr><tr><td><p>Gemcitabine</p></td><td><p>Common ↑ ALT/AST; ↓ dose if ↑ bili</p></td></tr><tr><td><p>Methotrexate</p></td><td><p>↑ ALT/AST, rarely fibrosis</p></td></tr><tr><td><p><b>Dermatologic</b></p></td><td><p>TKI (eg, imatinib)</p></td><td><p>Dermatitis, can be severe (eg SJS)</p></td></tr></tbody></table>

Immune checkpoint inhibitors (_ICI; Science_ 2018;359:1350)

• mAb against co-inhibitory signaling molecules, which cancers can use to prevent antitumor immunity

• Targets & drugs include

Programmed cell death protein 1 (PD-1; T & pro-B cells): nivolumab, pembrolizumab

Prog. death-ligand 1 (PD-L1; tumor & immune cells): atezolizumab, avelumab, durvalumab

Cytotoxic T-lymphocyte-assoc. protein 4 (CTLA-4; T cells): ipilimumab

• Toxicity (_NEJM_ 2018; 378:158): increased with combination of CTLA-4 + PD-1/PD-L1

Most commonly **colitis** (CTLA-4), **pneumonitis** (PD-1/PD-L1), **hepatitis** (CTLA-4), **dermatitis**, **hypothyroidism** (PD-1) / **hypophysitis** (CTLA-4)

Rarely: myocarditis (can be fulminant), myositis, myelitis, uveitis, diabetes

• 治療: _multidisciplinary care_; hold ICI; give steroids, 排除 infection. If severe, consider TNF-α inhibitor for colitis, mycophenolic acid for hepatitis, hormones for endocrinopathy

Chimeric antigen receptor (CAR)-T cells (_Science_ 2018;359:1350)

• Autologous T cells with modified/chimeric receptor for Ag recognition and T cell activation without MHC or 2nd co-stim signal.

• CD19 CAR-T cells targeting B-cell malig. most developed: tisagenlecleucel, axicabtagene ciloleucel

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>CAR- T Toxicity</b></p></td></tr><tr><td><p><b>Syndrome</b></p></td><td><p><b>Mechanism &amp; 表現</b></p></td><td><p><b>治療</b></p></td></tr><tr><td><p>Cytokine release syndrome (CRS)</p></td><td><p>Due to proliferating CAR-T. Fevers to shock.</p></td><td><p>Anti-IL-6 (tocilizumab or siltuximab) + steroids if severe</p></td></tr><tr><td><p>CAR-T-cell-related encephalopathy syndrome (CRES)</p></td><td><p>Cerebral edema due to CAR-T in CNS. Delirium, aphasia, seizures, or death.</p></td><td><p>Steroids, ativan/keppra for seizures.</p></td></tr><tr><td><p>Hemophagocytic lymphohistiocytosis (HLH)</p></td><td><p>Rare hyper-inflammation. Ferritin &gt;10k &amp; liver/kidney/lung toxicity.</p></td><td><p>CRS Rx, etoposide ± intrathecal cytarabine if not improving <span>(</span><span><i>Nat Rev Clin Onc</i></span> <span>20</span><span>1</span><span>8;</span><span>1</span><span>5:47)</span></p></td></tr></tbody></table>
